Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198. On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-10-01
|
| Series: | Biologics : Targets & Therapy |
| Online Access: | http://www.dovepress.com/corrigendum-treatment-and-management-of-myelofibrosis-in-the-era--a14840 |